Swiss companies have committed $27 billion in investment to the United States during the period from January to April, according to figures cited in an internal communication from the Swiss-American Chamber of Commerce that was reported by NZZ am Sonntag.
The reported total is framed as part of a broader Swiss pledge made on Nov. 14 that Swiss firms would invest $200 billion in the U.S. over the following five years. That commitment accompanied a preliminary trade understanding under which U.S. President Donald Trump reduced punitive tariffs on Swiss goods to 15% from a prior 39% level; the higher rate had been imposed at the beginning of August.
The recent investments span several sectors. Major pharmaceutical companies are prominent among the announced projects: Novartis has disclosed two U.S. initiatives, including plans for a biomedical research centre in San Diego and a cancer-drug production facility in Texas. Roche is reported to be expanding output in North Carolina, and medical technology firm Ypsomed is building a new factory in the same state.
Outside life sciences, the shipping group MSC is establishing a new North American headquarters in Miami, with related spending on cruise and logistics operations included under that activity. Industrial manufacturers are also increasing U.S. capacity: machine tool maker Pfiffner Group and electronics firm Elma are cited as expanding production facilities in the United States.
Commenting on the investment push, Swiss-American Chamber of Commerce Chief Executive Rahul Sahgal was quoted as saying: "We are model students and we fulfil our promises."
At the same time, Washington this week announced new tariffs aimed at countries it says are not doing enough to combat forced labour. The newspaper also reported that, under that measure, the U.S. plans a 12.5% tariff on Swiss goods compared with 10% for goods from the European Union.
The information reported by the Swiss-American Chamber of Commerce provides a snapshot of early-year deployment of capital tied to a high-profile bilateral commercial arrangement. Announced projects cover research, manufacturing and corporate presence, with a concentration in life sciences, logistics and industrial manufacturing.
While the reporting details specific company commitments and some geographic concentrations within the U.S., it does not provide a sector-by-sector breakdown of the full $27 billion total or a timeline for completion across the projects cited.